ARTICLE | Financial News
MeiraGTx plans IPO
May 15, 2018 10:17 PM UTC
MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan.
The company is developing a portfolio of gene therapies with programs in ophthalmic disease, salivary gland disease and neurodegenerative disorders. The company's AAV-CNGB3, an adeno-associated virus (AAV) vector that delivers the cyclic nucleotide gated channel beta 3 (CNGB3) gene, is in Phase I/II to treat achromatopsia. The candidate has Orphan Drug and rare pediatric disease designations from FDA and Orphan Drug and PRIME designations from EMA in the indication...
BCIQ Company Profiles